University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.
Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.
Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.
A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.
The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
Global research initiative Cancer Grand Challenges announced on March 5 seven new challenges which it deems to be among the biggest questions in cancer, offering international researchers the chance to form teams to apply for up to $25 million (or £20 million) in funding to take them on.
Color Health announced Large Language Expert, a new AI application architecture to address challenges that prevent GenAI from becoming a trusted co-pilot in clinical decision-making.
Tempus AI Inc. and Stemline Therapeutics Inc. announced a new collaboration. The two companies will leverage Next—Tempus’ AI-enabled care pathway intelligence platform—to help clinicians determine when an ESR1 test may be appropriate.
DeepHealth and ConcertAI’s TeraRecon announced a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow.
On Jan. 21, President Donald Trump announced the launch of the Stargate Project, a $500 billion artificial intelligence infrastructure project designed to revolutionize healthcare.
